Change Language

Select Language

Global Travel Vaccines Market to Grow at 11.1% During 2022-2027, Propelled by Increasing International Tourism

Published on Jan 04, 2022

The latest report by IMARC Group titled, “Travel Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2027” finds that the global travel vaccines market reached a value of US$ 3.2 Billion in 2021. Travel vaccines, also known as travel immunizations, are shots that travelers receive before visiting certain parts of the world where there is a high risk of developing certain diseases. These vaccines introduce the disease-causing microbes into the bloodstream to help the human body produce antibodies that will fight off the same if the person is exposed to the disease again. These shots must be taken at least 4 to 6 weeks before traveling, as it gives enough time for the immunization to start working efficiently.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Travel Vaccines Market Trends:

The market is primarily driven by the rising occurrence of infectious and travel-related diseases such as diphtheria, Japanese encephalitis, meningitis, and yellow fever. In addition, there has been significant growth in international tourism due to rapid globalization and reduced international airfares. As a result, the demand for travel vaccines has witnessed substantial growth across the globe. Besides this, combination vaccines are gaining popularity among travelers as they protect against multiple diseases and reduce the number of vaccines required, thereby contributing to the market growth. Moreover, travel vaccines have become an essential requirement in an international travelers list as governments of numerous countries have mandated that travelers should be vaccinated before visiting disease-prone regions. For instance, the National Health Service (NHS) is providing several free travel vaccines for diseases, such as cholera, polio, typhoid and hepatitis A, in the United Kingdom to reduce the risk of these diseases being spread across the country. On account of these factors, IMARC Group expects the market to grow at a CAGR of 11.1% during 2022-2027.

Market Summary:

  • On the basis of the composition, the market has been bifurcated into mono and combination vaccines. At present, combination vaccines account for the majority of the market share.
  • Based on the disease, the market has been segmented into hepatitis A, DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, varicella, Japanese encephalitis, and others. Amongst these, hepatitis A exhibits a clear dominance in the market.
  • On the geographical front, North America holds the leading position in the market. Other major regions include Europe, Asia Pacific, Middle East and Africa, and Latin America.
  • The competitive landscape of the market has also been analyzed in the report, with some of the major players being GlaxoSmithKline Pharmaceuticals Limited, Sanofi Pasteur, Merck & Co., Inc., Novartis AG,  Pfizer Inc., ALK -Abelló A/S, Bavarian Nordic A/S, Crucell (Subsidiary of Johnson & Johnson), CSL  Limited, AstraZeneca PLC, Altimmune, Inc., Abbott Laboratories, Hoffmann-La Roche, Inc.


About Us                                                                      

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

30 N Gould St Ste R

Sheridan, WY 82801 USA - Wyoming

Email: Sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

Americas: - +1 631 791 1145 | Africa and Europe: - +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com